Inhibition of ERK1/2 activity by the MEK1/2 inhibitor AZD6244 (ARRY-142886) induces human multiple myeloma cell apoptosis in the bone marrow microenvironment: A new therapeutic strategy for MM.

被引：2
|
作者：
Tai, Yu-Tzu [1 ]
Li, Xian-Feng [1 ]
Breitkreutz, Iris [1 ]
Song, Weihua [1 ]
Burger, Peter [1 ]
Rumizen, Matthew [1 ]
Hideshima, Teru [1 ]
Podar, Klaus [1 ]
Ghobrial, Irene [1 ]
Schlossman, Robert [1 ]
Richardson, Paul [1 ]
Munshi, Nikhil C. [1 ]
Anderson, Kenneth C. [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
10.1182/blood.V108.11.3460.3460
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3460
引用
收藏
页码：987A / 987A
页数：1
相关论文
共 36 条
  • [1] Inhibition of extracellular signal-regulated kinase1/2 mitogen-activated protein kinase (MAPK/ERK1/2) activity by MEK1/2 inhibitor AZD6244 (ARRY-142886) induces human multiple myeloma (MM) cell apoptosis and inhibits osteoclasts within the bone marrow (BM) microenvironment
    Tai, Y. T.
    Hideshima, T.
    Song, W.
    Li, X. F.
    Rumizen, M.
    Burger, P.
    Morrison, A.
    Podar, K.
    Schlossman, R.
    Richardson, P.
    Munshi, N. C.
    Ghobrial, I.
    Smith, P.
    Anderson, K. C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 147 - 147
  • [2] Validation and use of a biomarker for clinical development of the MEK1/2 inhibitor ARRY-142886 (AZD6244).
    Doyle, MP
    Yeh, TC
    Suzy, B
    Morrow, M
    Lee, PA
    Hughes, AM
    Cartlidge, S
    Wallace, E
    Lyssikatos, J
    Eckhardt, SG
    Winkler, JD
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 210S - 210S
  • [3] A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma
    Holkova, Beata
    Zingone, Adriana
    Kmieciak, Maciej
    Bose, Prithviraj
    Badros, Ashraf Z.
    Voorhees, Peter M.
    Baz, Rachid
    Korde, Neha
    Lin, Hui-Yi
    Chen, Jin-Qiu
    Herrmann, Michelle
    Xi, Liqiang
    Raffeld, Mark
    Zhao, Xiuhua
    Wan, Wen
    Tombes, Mary Beth
    Shrader, Ellen
    Weir-Wiggins, Caryn
    Sankala, Heidi
    Hogan, Kevin T.
    Doyle, Austin
    Annunziata, Christina M.
    Wellons, Martha
    Roberts, John D.
    Sullivan, Daniel
    Landgren, Ola
    Grant, Steven
    CLINICAL CANCER RESEARCH, 2016, 22 (05) : 1067 - 1075
  • [4] Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886)
    Balagula, Yevgeniy
    Huston, Katherine Barth
    Busam, Klaus J.
    Lacouture, Mario E.
    Chapman, Paul B.
    Myskowski, Patricia L.
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (05) : 1114 - 1121
  • [5] AZD6244 (ARRY-142886), a potent and selective MEK1/2 inhibitor blocks the ERK1/2 signaling pathway, inhibits osteoclast differentiation and activation in multiple myeloma: Clinical implications.
    Breitkreutz, Iris
    Vallet, Sonia
    Raab, Marc S.
    Li, Xianfeng
    Raje, Noopur
    Hideshima, Teru
    Chauhan, Dharminder
    Munshi, Nikhil
    Anderson, Kenneth C.
    Tai, Yu-Tzu
    BLOOD, 2006, 108 (11) : 989A - 989A
  • [6] Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886)
    Yevgeniy Balagula
    Katherine Barth Huston
    Klaus J. Busam
    Mario E. Lacouture
    Paul B. Chapman
    Patricia L. Myskowski
    Investigational New Drugs, 2011, 29 : 1114 - 1121
  • [7] AZD6244, a MEK1/2 inhibitor, inhibits osteoclast differentiation and activity in multiple myeloma
    Breitkreutz, I.
    Raab, M. S.
    Vallet, S.
    Hideshima, T.
    Raje, N.
    Chauhan, D.
    Munshi, N.
    Richardson, P.
    Tai, Y. T.
    Anderson, K. C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 131 - 131
  • [8] The MEK1/2 inhibitor AZD6244 (ARRY-142886) downregulates constitutive and adhesion-induced c-MAF oncogene expression and its downstream targets in human multiple myeloma.
    Tai, Yu-Tzu
    Tonon, Giovanni
    Li, Xian-Feng
    Rumizen, Matthew
    Song, Weihua
    Morrison, Aileen
    Burger, Peter
    Munshi, Nikhil C.
    Anderson, Kenneth C.
    BLOOD, 2006, 108 (11) : 988A - 988A
  • [9] Case studies showing clinical signs and management of cutaneous toxicity of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in patients with solid tumours
    Desar, Ingrid M. E.
    Bovenschen, H. Jorn
    Timmer-Bonte, Anja J. N. H.
    Cantarini, Mireille V.
    van der Graaf, Winette T. A.
    van Rossum, Michelle M.
    van Herpen, Carla M. L.
    ACTA ONCOLOGICA, 2010, 49 (01) : 113 - 116
  • [10] Targeting ERK1/2 activation and proliferation in human primary schwannoma cells with MEK1/2 inhibitor AZD6244
    Ammoun, Sylwia
    Ristic, Natalia
    Matthies, Cordula
    Hilton, David A.
    Hanemann, C. Oliver
    NEUROBIOLOGY OF DISEASE, 2010, 37 (01) : 141 - 146
1234